Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
REVENUE OF LEQEMBI (PRELIMINARY BASIS)
Leqembi (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union
Notice Concerning Commencement of Tender Offer for Share Certificates, etc., of EcoNaviSta Inc. (Securities Code: 5585)
Eisai Announces Appointments of Corporate Officers
Notification Regarding Changes in Representative Corporate Officers
Notice of Nominees for Directors
Eisai, Apr-Dec (Cumulative 3Q) Net Income Increases by 56%, Exceeds Full-Year Plan
FY 2024 (Ending March 31, 2025) Third Quarter Financial Results Reference Data
CONSOLIDATED FINANCIAL REPORT [IFRS] for the Nine-Month Period Ended December 31, 2024
FDA Approves LEQEMBI(lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
FDA Accepts LEQEMBI(lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
Eisai Announces Completion of Cancellation of Treasury Shares
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease
Financial Results for the Six-Month Period Ended September 30,2024 Reference Data
CONSOLIDATED FINANCIAL REPORT [IFRS] for the Six-Month Period Ended September 30, 2024
Eisai Co., Ltd., July-September (2Q) Net Income Increases by 4.0 times
REVENUE OF LEQEMBI (PRELIMINARY BASIS)
Eisai Announces Status and Completion of Acquisition of Own Shares
Eisai Announces Status Relating to Acquisition of Own Shares
Eisai Announces Status Relating to Acquisition of Own Shares